N1-Methylpseudo-UTP
Modified triphosphate for stabilizing mRNA
| Size | Catalog No. | Price |
|---|---|---|
| 1 µmol | BCT-37-S | € 90,00 |
| 5 µmol | BCT-37-L | € 350,00 |
Chemical Properties
-
Molecular Formula
C10H17N2O15P3 (free acid)
-
Shelf Life
12 months unopened after receipt
-
Storage Conditions
-20 °C, dark, dry
-
Molecular Weight
498.10 g/mol (free acid)
-
Purity
≥ 98.5% (HPLC)
-
Physical State
colorless solution (100 mM, pH 7.5)
-
CAS Number
1428903-59-6
-
Absorption (max)
λmax = 271 nm
-
Ɛ (max)
8877 cm-1M-1
Product Information
N1-methylpseudo-UTP is a modified nucleotide, used for synthesizing mRNA with reduced immunogenicity and improved stability. It was reported that N1-methylpseudouridine (m1Ψ) modification alone or in combination with 5-methylcytidine (m5C) exhibited superiority over pseudouridine (Ψ) or m5C/Ψ-modified mRNA platform by providing up to ~ 44-fold (when comparing double modified mRNAs) and ~ 13-fold (when comparing single modified mRNAs) higher reporter gene expression in mammalian cells and mice, respectively. Moreover, compared with (m5C/)Ψ-modified mRNAs, (m5C/)m1Ψ-modified mRNAs showed reduced intracellular innate immunogenicity and resulted in improved cellular viability after in vitro transfection.[1] Therefore, N1-methylpseudouridine Triphosphate can serve as a powerful ingredient for synthesizing new mRNA drugs with better performance.
LITERATURE
[1] N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice, O. Andries et al., 2015, Journal of Controlled Release, Vol. 217, p. 337-344.
https://doi.org/10.1016/j.jconrel.2015.08.051
Multicomponent Lipid Nanoparticles for RNA Transfection, N. Gretskaya et al., 2023, Pharmaceutics, Vol. 15(4), 1289.
https://doi.org/10.3390/pharmaceutics15041289
CpG oligodeoxynucleotide developed to activate primate immune responses promotes antitumoral effects in combination with a neoantigen-based mRNA cancer vaccine, Q. Li et al., 2021, Drug Design, Development and Therapy, p. 3953-3963.